Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma

Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Journal of Clinical Oncology (Impact Factor: 17.88). 02/2010; 28(9):1606-10. DOI: 10.1200/JCO.2009.25.5356
Source: PubMed

ABSTRACT With whole-body magnetic resonance imaging (wb-MRI), almost the whole bone marrow compartment can be examined in patients with monoclonal plasma cell disease. Focal lesions (FLs) detected by spinal MRI have been of prognostic significance in symptomatic multiple myeloma (sMM). In this study, we investigated the prognostic significance of FLs in wb-MRI in patients with asymptomatic multiple myeloma (aMM).
Wb-MRI was performed in 149 patients with aMM. The prognostic significance of the presence and absence, as well as the number, of FLs for progression into sMM was analyzed.
FLs were present in 28% of patients. The presence per se of FLs and a number of greater than one FL were the strongest adverse prognostic factors for progression into sMM (P < .001) in multivariate analysis. A diffuse infiltration pattern in MRI, a monoclonal protein of 40 g/L or greater, and a plasma cell infiltration in bone marrow of 20% or greater were other adverse prognostic factors for progression-free survival in univariate analysis.
We recommend use of wb-MRI for risk stratification of patients with asymptomatic multiple myeloma.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Smoldering myeloma is a heterogeneous clinical entity where a subset of patients has a very indolent course of disease that mimics MGUS-like state while others have a more aggressive course that has been described as "early myeloma". It is defined as either serum M-protein ≥3 g/L or ≥10% monoclonal plasma cells in the bone marrow. There are currently no molecular factors to differentiate risks of progression for these patients. Current recommendations of therapy are still observation or enrollment on clinical trials. However, new definitions of active MM were recently agreed by the International Myeloma Working Group that may alter the timing of therapy for many patients with asymptomatic disease. Based on emerging data of therapy in theses patients, it seems reasonable to believe that future recommendations for therapy of patients with smoldering myeloma will become an increasingly important topic. In this article, we review the current knowledge of this disease and risk factors associated with progression. We also examine biological insights and alterations that occur in the tumor clone and the surrounding bone marrow niche. Finally, we review clinical trials that have been performed in these patients and provide recommendations for follow up of patients with this unique disease entity.
    Blood 10/2014; 124(23). DOI:10.1182/blood-2014-08-551549 · 9.78 Impact Factor
  • Leukemia 07/2014; 28(12). DOI:10.1038/leu.2014.230 · 9.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by the presence of one or both features of serum M-protein at least 30 g/l and bone marrow plasma cell infiltration at least 10%. The standard of care is no treatment until symptomatic progression occurs. However, the risk of progression to active multiple myeloma is not uniform, and several markers are useful for identifying SMM patients at high risk of progression to active multiple myeloma. Overall, the presence of these factors is useful to stratify SMM patients according to their risk but the forthcoming challenge is to identify high and ultra-high-risk SMM patients because they can benefit from early treatment.
    Current Opinion in Oncology 09/2014; 26(6). DOI:10.1097/CCO.0000000000000121 · 3.76 Impact Factor

Full-text (2 Sources)

Available from
May 15, 2014